Emerging Immunologic Therapies for Multiple Sclerosis: Impact on Managed Care & Specialty Pharmacy
An online CPE/CNE activity repurposing content derived from the Satellite Symposium convened at the AMCP Managed Care & Specialty Pharmacy Annual Meeting 2019
June 1, 2019 – May 31, 2020
Archived, for viewing purposes only.
Recent advances in the field of immunology and the increasing recognition of inflammation are re-shaping the conceptualization of MS, with potential implications of new agents expanding the current landscape of treatment options.
This online CPE/CNE activity will examine the crucial role of managed care pharmacists in MS disease management programs, especially as new immune-directed agents emerge in the application of current evidence-based diagnoses, guideline data, and pharmacy-based managed care best practices in reducing the clinical and economic burdens related to this complex chronic disorder while optimizing patient outcomes.
After participating in this online activity, the learner should be able to:
- Discuss characteristics of current and emerging MS therapies, including mechanism of action, dosage and administration, adverse effects, and drug interactions;
- Describe the immune-mediated mechanisms of MS that may serve as immune targets for therapeutic interventions;
- Explain the relationship between medication adherence and MS disease control, and potential strategies for overcoming barriers to adherence;
- Review how a pharmacy-based practice model fosters increased accessibility, convenience, patient confidence and ultimately, improved patient outcomes by incorporating specialty medication management into transitions in care, admission and discharge quality indicators, readmissions, and other quality care measures.
- Illustrate how pharmacists, by serving as the regular point of contact, can encourage improved compliance, appropriate medication use, and provide ongoing safety monitoring, for quicker interventions.